Moderna to start developing a seasonal flu vaccine

/ / News

Shares of Moderna Inc. gained 3.8% in premarket trading on Thursday after the company said it plans to start developing a seasonal flu vaccine. “We are increasing our investment in vaccines and we will develop a seasonal flu vaccine given the unmet need for highly effective vaccines,” Moderna CEO Stéphane Bancel said in a news release. The preclinical company is currently running a Phase 3 clinical trial for its mRNA COVID-19 vaccine candidate. Moderna’s stock has soared 251.9% this year, while the S&P 500 is up 4.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.